Intertek has acquired Melbourn Scientific Ltd., a provider of analysis and development services for the pharma, biopharma, and healthcare industries. Located in Royston, UK, Melbourn employs 80 staff and has a 20,000-sq.-ft. GMP facility that has been inspected by the MHRA and the FDA. Financial terms were not disclosed.
 
Melbourn offers services including formulation and product development, analytical method development and validation, stability studies and QC release testing, with expertise in characterization of orally inhaled and intra-nasal products (OINDP) and transdermal devices, as well as conventionally delivered medicines.
 
Dr. Andrew Swift, senior vice president of Intertek Chemicals and Pharmaceuticals, said, “Combining Intertek’s GMP/ GLP pharmaceutical/ biopharmaceutical studies and our advanced capabilities for measuring device/ drug interaction with Melbourn’s expertise in OINDP drug characterization provides a unique and compelling offering to clients. Adding in our global reach and regulatory services, Intertek now offers a comprehensive and global end to end expert service to support drug development which is unmatched by current competitors.”